
Global Transient Receptor Potential Cation Channel Subfamily V Member 1 Market Growth (Status and Outlook) 2025-2031
Description
According to this study, the global Transient Receptor Potential Cation Channel Subfamily V Member 1 market size will reach US$ million by 2031.
United States market for Transient Receptor Potential Cation Channel Subfamily V Member 1 is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Transient Receptor Potential Cation Channel Subfamily V Member 1 is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Transient Receptor Potential Cation Channel Subfamily V Member 1 is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Transient Receptor Potential Cation Channel Subfamily V Member 1 players cover Amgen Inc, Amorepacific Corp, BCN Peptides SA, Centrexion Therapeutics Corp, Daewoong Pharmaceutical Co Ltd, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
LPI (LP Information)' newest research report, the “Transient Receptor Potential Cation Channel Subfamily V Member 1 Industry Forecast” looks at past sales and reviews total world Transient Receptor Potential Cation Channel Subfamily V Member 1 sales in 2024, providing a comprehensive analysis by region and market sector of projected Transient Receptor Potential Cation Channel Subfamily V Member 1 sales for 2025 through 2031. With Transient Receptor Potential Cation Channel Subfamily V Member 1 sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Transient Receptor Potential Cation Channel Subfamily V Member 1 industry.
This Insight Report provides a comprehensive analysis of the global Transient Receptor Potential Cation Channel Subfamily V Member 1 landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Transient Receptor Potential Cation Channel Subfamily V Member 1 portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Transient Receptor Potential Cation Channel Subfamily V Member 1 market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Transient Receptor Potential Cation Channel Subfamily V Member 1 and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Transient Receptor Potential Cation Channel Subfamily V Member 1.
This report presents a comprehensive overview, market shares, and growth opportunities of Transient Receptor Potential Cation Channel Subfamily V Member 1 market by product type, application, key players and key regions and countries.
Segmentation by Type:
CMX-020
CA-016
DD-04107
Others
Segmentation by Application:
Ophthalmology
Immunology
Muscle Spasm
Pruritus
Abdominal Pain
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Amgen Inc
Amorepacific Corp
BCN Peptides SA
Centrexion Therapeutics Corp
Daewoong Pharmaceutical Co Ltd
DoNatur GmbH
Flex Pharma Inc
Grunenthal GmbH
Kyowa Hakko Kirin Co Ltd
Medifron DBT Co Ltd
Neurim Pharmaceuticals Ltd
Pila Pharma AB
Sylentis SAU
Toray Industries Inc
Vitality Biopharma Inc
Please note: The report will take approximately 2 business days to prepare and deliver.
United States market for Transient Receptor Potential Cation Channel Subfamily V Member 1 is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Transient Receptor Potential Cation Channel Subfamily V Member 1 is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Transient Receptor Potential Cation Channel Subfamily V Member 1 is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Transient Receptor Potential Cation Channel Subfamily V Member 1 players cover Amgen Inc, Amorepacific Corp, BCN Peptides SA, Centrexion Therapeutics Corp, Daewoong Pharmaceutical Co Ltd, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
LPI (LP Information)' newest research report, the “Transient Receptor Potential Cation Channel Subfamily V Member 1 Industry Forecast” looks at past sales and reviews total world Transient Receptor Potential Cation Channel Subfamily V Member 1 sales in 2024, providing a comprehensive analysis by region and market sector of projected Transient Receptor Potential Cation Channel Subfamily V Member 1 sales for 2025 through 2031. With Transient Receptor Potential Cation Channel Subfamily V Member 1 sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Transient Receptor Potential Cation Channel Subfamily V Member 1 industry.
This Insight Report provides a comprehensive analysis of the global Transient Receptor Potential Cation Channel Subfamily V Member 1 landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Transient Receptor Potential Cation Channel Subfamily V Member 1 portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Transient Receptor Potential Cation Channel Subfamily V Member 1 market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Transient Receptor Potential Cation Channel Subfamily V Member 1 and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Transient Receptor Potential Cation Channel Subfamily V Member 1.
This report presents a comprehensive overview, market shares, and growth opportunities of Transient Receptor Potential Cation Channel Subfamily V Member 1 market by product type, application, key players and key regions and countries.
Segmentation by Type:
CMX-020
CA-016
DD-04107
Others
Segmentation by Application:
Ophthalmology
Immunology
Muscle Spasm
Pruritus
Abdominal Pain
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Amgen Inc
Amorepacific Corp
BCN Peptides SA
Centrexion Therapeutics Corp
Daewoong Pharmaceutical Co Ltd
DoNatur GmbH
Flex Pharma Inc
Grunenthal GmbH
Kyowa Hakko Kirin Co Ltd
Medifron DBT Co Ltd
Neurim Pharmaceuticals Ltd
Pila Pharma AB
Sylentis SAU
Toray Industries Inc
Vitality Biopharma Inc
Please note: The report will take approximately 2 business days to prepare and deliver.
Table of Contents
112 Pages
- *This is a tentative TOC and the final deliverable is subject to change.*
- 1 Scope of the Report
- 2 Executive Summary
- 3 Transient Receptor Potential Cation Channel Subfamily V Member 1 Market Size by Player
- 4 Transient Receptor Potential Cation Channel Subfamily V Member 1 by Region
- 5 Americas
- 6 APAC
- 7 Europe
- 8 Middle East & Africa
- 9 Market Drivers, Challenges and Trends
- 10 Global Transient Receptor Potential Cation Channel Subfamily V Member 1 Market Forecast
- 11 Key Players Analysis
- 12 Research Findings and Conclusion
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.